Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic
lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were …

A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase in the B-cell receptor signaling
pathway. In randomized trials, ibrutinib is effective asfirst-line treatment of chronic …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …

Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …

Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an
unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated …

PURPOSE Randomized trials established the superiority of ibrutinib-based therapy over
chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free …

Observation is the current standard of care for patients with early-stage asymptomatic
chronic lymphocytic leukemia (CLL), as chemotherapy-based interventions have failed to …

Ibrutinib, approved by the US Food and Drug Administration (FDA), is an inhibitor of Bruton
tyrosine kinase (BTK). 1-5 Ibrutinib use is associated with atrial fibrillation (AF), with an …